| SCYX |
SCYNEXIS, Inc. |
Common Stock, par value $0.001 per share |
10% |
$15,733,622 |
|
4,076,068 |
0% |
Great Point Partners, LLC |
30 Sep 2026 |
| UNCY |
Unicycive Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
10% |
$7,228,095 |
|
11,473,166 |
|
Great Point Partners, LLC |
31 Dec 2024 |
| SCYX |
SCYNEXIS, Inc. |
Common Stock, par value $0.001 per share |
10% |
$7,101,055 |
|
7,978,713 |
|
Great Point Partners, LLC |
31 Mar 2026 |
| PMN |
PROMIS NEUROSCIENCES INC. |
Common Shares, No Par Value per Share |
10% |
$400,714 |
-$2,107,681 |
954,082 |
-84% |
Great Point Partners, LLC |
31 Mar 2026 |
| SLGL |
Sol-Gel Technologies Ltd. |
Ordinary Shares, par value NIS 1.00 per share |
8.4% |
$11,561,684 |
|
274,363 |
|
Great Point Partners, LLC |
24 Mar 2026 |
| SLGL |
Sol-Gel Technologies Ltd. |
Ordinary Shares, par value NIS 1.00 per share |
7.3% |
$16,420,657 |
|
239,159 |
|
Great Point Partners, LLC |
30 Sep 2026 |
| PMN |
PROMIS NEUROSCIENCES INC. |
Common Shares, No Par Value per Share |
6.8% |
$7,210,099 |
-$954,542 |
650,731 |
-12% |
Great Point Partners, LLC |
30 Sep 2026 |
| RACC |
Research Alliance Corporation III |
Class A Ordinary Shares, par value $0.0001 per share |
6.5% |
$14,136,948 |
|
504,891 |
|
Great Point Partners, LLC |
04 Sep 2026 |
| JATT |
JATT II Acquisition Corp. |
Ordinary shares, par value $0.0001 per share |
6.4% |
$5,125,000 |
|
500,000 |
0% |
Great Point Partners, LLC |
30 Sep 2026 |
| AMAN |
AMANAT ACQUISITION CORP |
Class A ordinary shares |
6.4% |
$5,075,000 |
|
500,000 |
0% |
Great Point Partners, LLC |
30 Sep 2026 |
| JTTT |
JATT III Acquisition Corp |
Common |
5.1% |
$4,666,500 |
|
450,000 |
0% |
Great Point Partners, LLC |
30 Sep 2026 |
| LONA |
LeonaBio, Inc. |
Common Stock, $0.0001 par value per share |
5% |
$2,926,709 |
|
474,345 |
|
Great Point Partners, LLC |
28 Oct 2026 |
| OTLK |
Outlook Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
5% |
$4,484,400 |
|
2,220,000 |
0% |
Great Point Partners, LLC |
30 Jun 2025 |
| VTGN |
Vistagen Therapeutics, Inc. |
Common Stock, $0.001 par value per share |
5% |
$1,521,317 |
|
2,055,834 |
0% |
Great Point Partners, LLC |
31 Dec 2025 |
| OPTN |
OPTINOSE, INC. |
Common Stock, $0.001 par value per share |
4.9% |
$4,789,466 |
-$3,369,457 |
526,315 |
-41% |
Great Point Partners, LLC |
31 Mar 2025 |
| UNCY |
Unicycive Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
4.5% |
$3,472,993 |
|
796,558 |
0% |
Great Point Partners, LLC |
30 Sep 2025 |
| ZURA |
Zura Bio Limited |
Class A Ordinary Shares |
4.4% |
$25,422,058 |
+$2,412,000 |
4,215,930 |
+10% |
Great Point Partners, LLC |
31 Mar 2026 |
|
Inventiva S.A. |
Ordinary shares, nominal value 0.01 Euro per share |
3.5% |
|
|
6,783,269 |
-21% |
Great Point Partners, LLC |
31 Dec 2025 |
| VOR |
VOR BIOPHARMA INC. |
Common Stock, $0.0001 par value per share |
3.3% |
$18,578,651 |
+$1,839,021 |
1,370,107 |
+11% |
Great Point Partners, LLC |
31 Dec 2025 |
| NGNE |
NEUROGENE INC. |
Common Stock, par value $0.000001 per share |
3% |
$6,822,947 |
|
442,761 |
|
Great Point Partners, LLC |
31 Dec 2024 |
| CNTX |
Context Therapeutics Inc. |
Common Stock |
2.4% |
$5,864,860 |
-$6,406,463 |
2,238,496 |
-52% |
Great Point Partners, LLC |
31 Mar 2026 |